Parasol Therapeutics, a Cambridge, MA-based developer of treatments and diagnostics for influenza and other viruses, has raised $3.2 million in debt and equity financing, according to an SEC filing. Parasol, which Xconomy reported has previously raised $3.5 million in seed financing, is developing new therapies for flu based on discoveries in the MIT lab of professor Ram Sasisekharan related to how viruses attach to sugar chains on the surfaces of cells to infect them. Previous investors in the startup include initial backer Polaris Venture Partners, of Waltham, MA, Flagship Ventures, in Cambridge, and Lux Capital in New York. Polaris officials have not yet responded to a request for comment on this financing.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
